Hunan Jingfeng Pharmaceutical (000908) fair value: what the stock is really worth
As of Sep 30, 2026: fair value of Hunan Jingfeng Pharmaceutical ¥3.02, price ¥5.99, upside -49.6%, quality 51 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Hunan Jingfeng Pharmaceutical for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 3, 2026.
How to read this chart
60‑month range ¥0.7200 – ¥9.23 · fair‑value band ¥2.15 – ¥4.02 · the ¥5.99 price screens above the ¥3.02 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Oct 3, 2026.
Follow Hunan Jingfeng Pharmaceutical in your weekly email
Every Wednesday you see whether Hunan Jingfeng Pharmaceutical is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
CSPC Hunan Jingfeng Pharmaceutical Co., Ltd. manufactures and sells chemical drugs and biological agents in China. The company's principal product is sodium hyaluronate injection for use in orthopedics and surgery applications.
Show more
CSPC Hunan Jingfeng Pharmaceutical Co., Ltd. manufactures and sells chemical drugs and biological agents in China. The company's principal product is sodium hyaluronate injection for use in orthopedics and surgery applications. It also offers ophthalmic equipment and API products, as well as engages in the research and development of antitumor, cancer, and cardiovascular drugs; and distributed in the fields of cardiovascular disease, orthopedic pain disease, tumor disease, women and children. The company was formerly known as Hunan Jingfeng Pharmaceutical Co.,Ltd. and changed its name to CSPC Hunan Jingfeng Pharmaceutical Co., Ltd. in April 2026. The company was founded in 1998 and is headquartered in Changde, China.
Stock analysis
Hunan Jingfeng Pharmaceutical (000908) currently trades at ¥5.99, while our model-based Fair Value estimate is ¥3.02, 49.6% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth DCF group reads highest at a median of ¥0.4800 per share, and 0 of the 10 models we run sit above the ¥5.99 price.
Bear case: the DCF Models group reads lowest at ¥0.4700, and 10 of the 10 models stay below the price. Evidence for this calculation is low.
Scenario range: ¥2.15 (bear) to ¥4.02 (bull), the price of ¥5.99 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 51/100 (solid quality), in the Healthcare sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
Hunan Jingfeng Pharmaceutical reported revenue of 378M CNY in FY2025 versus 811M CNY in FY2021, a compound −17.4%/yr. Reported net income was −80.9M CNY in FY2025.
Key figures
Market cap 10.5B CNY (≈ $1.6B) · P/S ratio 26.5 · EPS (TTM) ¥−0.0500 · Dividend yield 0.1% · Net margin −21.4% · Return on equity −3.9% · Return on assets (EBIT) −2.1% · Operating margin 0.7%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (medium confidence).
What moves the price
The share trades about 35% below its 52-week high and 31% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −1% fair-value upside, at −50%, 000908 screens richer than that median.
Fair Value models
The price assumes far more growth than our models allow for, so the models scatter widely (¥0.0100 to ¥0.5700). Read the Fair Value as a cautious anchor, not a price target; the Growth Forecast section shows what the price assumes.
Bear ¥2.15Fair Value ¥3.02Bull ¥4.02
Price ¥5.99 · Upside -49.6%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.23/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−9.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−23.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−15.5%
Start year 2020 (pandemic). Over 10 years: −17.1% a year
Revenue growth 30 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.9%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−128.0% (2020) → −7.4% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+47.2%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (China: IMF forecast 1.7% a year to 2030, 1.4% from 2016 to 2025) that is about +44.8% a year for the price.
Compare Hunan Jingfeng Pharmaceutical with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - General · 74 stocks
Beats the industry median on 1/10 measures
Overall it trails its industry peers.
Valuation
Quality Score51 · Below median
Fair Value upside−49.6% · Below median
Profitability
Return on assets−1.3% · Bottom 25%
Net margin (TTM)−10.7% · Bottom 25%
Operating margin (TTM)0.7% · Bottom 25%
Growth and dividend
Revenue growth21.5% · Top 25%
Dividend yield (TTM)0.1% · Bottom 25%
Balance sheet
Debt / equity3.12× · Highest 25%
Valuation Multiplesvs Drug Manufacturers - General median · lower = cheaper
P/S (TTM)3.96× · Pricier than median
P/FCF28.7× · Pricier than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 19
FUTURE (revenue growth)100· sector 33
PAST (return on equity)0· sector 40
HEALTH (low debt)0· sector 92
DIVIDEND (yield)2· sector 41
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Hunan Jingfeng Pharmaceutical (000908) overvalued or undervalued?
As of Oct 3, 2026, our model estimates a fair value of ¥3.02 versus a price of ¥5.99, about −50% upside (overvalued).
What is the fair value of 000908?
Our model-based fair value for Hunan Jingfeng Pharmaceutical is ¥3.02 (as of Oct 3, 2026), built from audited fundamentals. The current price: ¥5.99.
What is the quality score of 000908?
Hunan Jingfeng Pharmaceutical has a Quality Score of 51/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Hunan Jingfeng Pharmaceutical (000908)?
Our model-based price target is the fair value of ¥3.02 (as of Oct 3, 2026) from 10 valuation models. Cautious scenario ¥2.15, optimistic scenario ¥4.02. It is a calculation from audited fundamentals, not an analyst target.
What is the Hunan Jingfeng Pharmaceutical stock forecast for 2026?
Our models put fair value at ¥3.02, about −50% upside versus a price of ¥5.99 (overvalued). Cautious scenario ¥2.15, optimistic scenario ¥4.02. The calculation is refreshed regularly with new filings.
What is the revenue of Hunan Jingfeng Pharmaceutical (000908)?
Hunan Jingfeng Pharmaceutical reported trailing-twelve-month revenue of about 397M CNY (latest available figure, as of Oct 3, 2026).
Does Hunan Jingfeng Pharmaceutical pay a dividend?
Hunan Jingfeng Pharmaceutical currently shows a dividend yield of about 0.10% relative to its recent price (as of Oct 3, 2026).
What growth is priced into Hunan Jingfeng Pharmaceutical (000908)?
For today's price to be fair in a discounted-cash-flow model, Hunan Jingfeng Pharmaceutical would have to grow free cash flow by +47.2 % per year for five years (discount rate 11.9 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew -15.5 % per year. As of Oct 3, 2026.
What discount rate (WACC) does the fair value of 000908 use?
Our models discount Hunan Jingfeng Pharmaceutical at 11.9 %: a base by market capitalisation (small), country premium for China. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Hunan Jingfeng Pharmaceutical that is +47.2 % per year a year over ten years, using the same discount rate (11.9 %) and the same formula as our fair value.
How much growth has Hunan Jingfeng Pharmaceutical (000908) delivered so far?
Over the past 5 years revenue at Hunan Jingfeng Pharmaceutical grew -15.5 % a year. The price currently implies +47.2 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Hunan Jingfeng Pharmaceutical (000908) growing?
The median revenue growth in the sector is +5.2 % a year. That is the yardstick for the growth priced into Hunan Jingfeng Pharmaceutical (+47.2 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Hunan Jingfeng Pharmaceutical (000908)?
The free-cash-flow yield on the price is 1.04 %: that much free cash flow Hunan Jingfeng Pharmaceutical produces per unit of market value. When it exceeds the discount rate of our models (11.9 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Hunan Jingfeng Pharmaceutical (000908)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Hunan Jingfeng Pharmaceutical it is ¥3.02 per share (as of Oct 3, 2026), against a price of ¥5.99. It is the blended result of 10 valuation models (cash flow, earnings, asset, dividend).
Is Hunan Jingfeng Pharmaceutical stock overvalued or undervalued in 2026?
As of Oct 3, 2026, 000908 trades above its calculated fair value: price ¥5.99, fair value ¥3.02, a gap of about −50% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 000908?
No. The price is what the market pays today (¥5.99); the fair value is what the company's own numbers justify (¥3.02). For Hunan Jingfeng Pharmaceutical the two are ¥2.97 per share apart. That gap is exactly why we show both numbers side by side.
How much is Hunan Jingfeng Pharmaceutical worth?
The market values Hunan Jingfeng Pharmaceutical at about 10.5B CNY (market capitalisation, as of Oct 3, 2026). Per share that is ¥5.99; our models calculate a fair value of ¥3.02 per share.
What do the bullish and bearish scenarios say about 000908?
Our models span a range for Hunan Jingfeng Pharmaceutical: cautious scenario ¥2.15, base ¥3.02, optimistic ¥4.02 per share (as of Oct 3, 2026, price ¥5.99). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Hunan Jingfeng Pharmaceutical (000908)?
Balance-sheet figures for Hunan Jingfeng Pharmaceutical (as of Oct 3, 2026): return on equity −3.9%, debt of 3.12 per unit of equity. They feed the Quality Score of 51/100, which measures business quality independently of the share price.
How far is 000908 from its 52-week high?
Hunan Jingfeng Pharmaceutical trades at ¥5.99, about 35% below its 52-week high of ¥9.23 and 31% above the low of ¥4.58 (as of Sep 30, 2026). Distance from the high says nothing about value: that is what the fair value of ¥3.02 is for.
Which stocks are comparable to Hunan Jingfeng Pharmaceutical?
From the same area (Healthcare) we also value Eli Lilly and Company, Johnson & Johnson,, AbbVie Inc, Roche Holding, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Hunan Jingfeng Pharmaceutical stock attractive at the current price?
The data as of Oct 3, 2026: price ¥5.99, calculated fair value ¥3.02 (−50%), Quality Score 51/100, from 10 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 000908 calculated?
We run Hunan Jingfeng Pharmaceutical through 10 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ¥3.02, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.9 % above its aggregate fair value. Hunan Jingfeng Pharmaceutical itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Hunan Jingfeng Pharmaceutical (000908)?
The closing price on Sep 30, 2026 was ¥5.99. Our model-based fair value is ¥3.02, about −50% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Hunan Jingfeng Pharmaceutical right now?
The price sits above even our optimistic bull case (¥4.02). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (51/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (¥2.15 to ¥4.02) leaves room in how you read the outcome.
Key figures of Hunan Jingfeng Pharmaceutical
How large is the market capitalisation of Hunan Jingfeng Pharmaceutical (000908)?
The market capitalisation of Hunan Jingfeng Pharmaceutical is 10.5B CNY (≈ $1.6B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Hunan Jingfeng Pharmaceutical (000908)?
The price-to-sales ratio of Hunan Jingfeng Pharmaceutical is 26.5 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Hunan Jingfeng Pharmaceutical (000908)?
Earnings per share at Hunan Jingfeng Pharmaceutical are ¥−0.0500. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Hunan Jingfeng Pharmaceutical (000908)?
The dividend yield of Hunan Jingfeng Pharmaceutical is 0.1%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Hunan Jingfeng Pharmaceutical (000908)?
The net margin of Hunan Jingfeng Pharmaceutical is −21.4% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Hunan Jingfeng Pharmaceutical (000908)?
The return on equity (ROE) of Hunan Jingfeng Pharmaceutical is −3.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Hunan Jingfeng Pharmaceutical (000908)?
On an EBIT basis the return on assets of Hunan Jingfeng Pharmaceutical is −2.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Hunan Jingfeng Pharmaceutical (000908)?
The operating margin of Hunan Jingfeng Pharmaceutical is 0.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Hunan Jingfeng Pharmaceutical (000908)?
Revenue at Hunan Jingfeng Pharmaceutical is growing +21.5% versus a year earlier (3y avg −23.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Hunan Jingfeng Pharmaceutical (000908)?
Earnings per share at Hunan Jingfeng Pharmaceutical are growing +167% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Hunan Jingfeng Pharmaceutical (000908) carry?
The net debt of Hunan Jingfeng Pharmaceutical is 113M CNY (fiscal year 2024, ≈ 2.1 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Hunan Jingfeng Pharmaceutical in the live analysis
One click puts Hunan Jingfeng Pharmaceutical on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
